Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 2121-2123, 1992;
This Article
Right arrow Order Full text via Infotrieve
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurobe, M.
Right arrow Articles by Hayashi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurobe, M.
Right arrow Articles by Hayashi, K.

Clinical Chemistry, Vol 38, 2121-2123, Copyright © 1992 by American Association for Clinical Chemistry

Fluorometric enzyme immunoassay of basic fibroblast growth factor with monoclonal antibodies

M Kurobe, A Kato, Y Takei and K Hayashi
Gifu Pharmaceutical University, Department of Molecular Biology, Japan.

We compared three different strategies for measuring basic fibroblast growth factor (bFGF) by fluorometric enzyme immunoassay (EIA). After optimizing conditions, we found that a primary anti-bFGF MAb directly conjugated with peroxidase gave the best detection limit for recombinant bFGF (approximately 30 ng/L, 3 pg/assay tube) in a two-site sandwich assay. The detection limit of methods based on biotinylated primary MAbs or on secondary antibodies followed by streptavidin- conjugated peroxidase was slightly lower than that of the above method. Using the most sensitive EIA examined in this study, we made a preliminary measurement of immunoreactive bFGF in sera of apparently healthy people and found it to be 190 (SD 32) ng/L (n = 48), in agreement with an earlier reported value (30-206 ng/L). Also, the concentration of immunoreactive bFGF in sera was above normal in 19 of 31 patients with stomach cancer.


The following articles in journals at HighWire Press have cited this article:


Home page
 Cardiovasc ResHome page
K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini
Biological activities of fibroblast growth factor-2 in the adult myocardium
Cardiovasc Res, January 1, 2003; 57(1): 8 - 19.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.